A Graph-Based Systems Biology Framework for Prioritizing Multi-Compound Interventions in Complex Disease Mechanisms
Keywords:
graph-based systems biology; multi-compound interventions; network pharmacology; disease modules; synergy prioritization; uncertainty propagationAbstract
Complex diseases are rarely explained by a single molecular lesion, and interventions that modulate one target often produce limited or transient benefit. Network and systems-biology approaches have clarified how disease phenotypes emerge from distributed molecular interactions, but the prioritization of multi-compound interventions remains methodologically fragmented. Pairwise synergy models are not designed to evaluate mechanism coverage across several disease modules, while single-compound network methods do not represent combination effects, redundancy, or cumulative safety burden. This manuscript develops a graph-based systems-biology framework that treats multi-compound prioritization as a constrained, mechanism-aware ranking problem. The framework integrates compounds, molecular targets, pathways, and disease modules into a heterogeneous intervention graph; converts heterogeneous evidence into calibrated edge weights; propagates compound-set effects through target engagement and module perturbation; and scores candidate sets using mechanism coverage, redundancy penalties, and off-target burden. Synergy is represented as complementarity at the target and module level rather than as an isolated pairwise phenotype. Uncertainty is propagated from edge evidence to candidate rankings, and the final decision rule balances expected benefit against evidence variance and model complexity. Analytical assessment shows where the framework is likely to outperform target-centric or signature-only strategies, especially when disease mechanisms are distributed and combinations must avoid overlapping or antagonistic effects. It also identifies boundary conditions involving module resolution, topological bias, dose context, and causal interpretation. The contribution is a transparent prioritization architecture for preclinical and translational hypothesis generation, not a validated clinical decision tool.
References
1. Barabási, A.-L., & Oltvai, Z. N. (2004). Network biology: Understanding the cell's functional organization. Nature Reviews Genetics, 5(2), 101–113. https://doi.org/10.1038/nrg1272
2. Kitano, H. (2002). Systems biology: A brief overview. Science, 295(5560), 1662–1664. https://doi.org/10.1126/science.1069492
3. Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690. https://doi.org/10.1038/nchembio.118
4. Yildirim, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007). Drug-target network. Nature Biotechnology, 25(10), 1119–1126. https://doi.org/10.1038/nbt1338
5. Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013). Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review. Pharmacology & Therapeutics, 138(3), 333–408. https://doi.org/10.1016/j.pharmthera.2013.01.016
6. Guney, E., Menche, J., Vidal, M., & Barabási, A.-L. (2016). Network-based in silico drug efficacy screening. Nature Communications, 7, 10331. https://doi.org/10.1038/ncomms10331
7. Cheng, F., Kovács, I. A., & Barabási, A.-L. (2019). Network-based prediction of drug combinations. Nature Communications, 10, 1197. https://doi.org/10.1038/s41467-019-09186-x
8. Chou, T.-C., & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27–55. https://doi.org/10.1016/0065-2571(84)90007-4
9. Loewe, S. (1953). The problem of synergism and antagonism of combined drugs. Arzneimittel-Forschung, 3(6), 285–290.
10. Bliss, C. I. (1939). The toxicity of poisons applied jointly. Annals of Applied Biology, 26(3), 585–615. https://doi.org/10.1111/j.1744-7348.1939.tb06990.x
11. Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., ... Golub, T. R. (2006). The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science, 313(5795), 1929–1935. https://doi.org/10.1126/science.1132939
12. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., ... Mesirov, J. P. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences, 102(43), 15545–15550. https://doi.org/10.1073/pnas.0506580102
13. Szklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., ... von Mering, C. (2021). The STRING database in 2021: Customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Research, 49(D1), D605–D612. https://doi.org/10.1093/nar/gkaa1074
14. Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., ... Wilson, M. (2018). DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46(D1), D1074–D1082. https://doi.org/10.1093/nar/gkx1037
15. HerbSyner_Finder: a network community-based model for identifying synergistic combinations from herbal medicines and complex systems. Targetome. 2026;2(2):0-0. doi: 10.48130/targetome-0026-001
16. Newman, M. E. J. (2006). Modularity and community structure in networks. Proceedings of the National Academy of Sciences, 103(23), 8577–8582. https://doi.org/10.1073/pnas.0601602103
17. Ideker, T., Ozier, O., Schwikowski, B., & Siegel, A. F. (2002). Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics, 18(Suppl. 1), S233–S240. https://doi.org/10.1093/bioinformatics/18.suppl_1.S233
18. Zhang, B., & Horvath, S. (2005). A general framework for weighted gene co-expression network analysis. Statistical Applications in Genetics and Molecular Biology, 4, Article 17. https://doi.org/10.2202/1544-6115.1128
19. Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B, 57(1), 289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x
20. Pearl, J. (2009). Causality: Models, reasoning, and inference (2nd ed.). Cambridge University Press.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 International Journal of Clinical and Translational Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



